Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-110 and Abiraterone in Metastatic Prostate Cancer
NCT05177042Phase 1Completed
- Sponsor
- Arvinas
- Start
- May 2022
- Primary completion
- Jul 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
Phase 1, open-label trial of bavdegalutamide in Metastatic Prostate Cancer (mPC) (2 arms), sponsored by Arvinas. Primary endpoints: Dose Limiting Toxicities at Day 28, Recommended Phase 2 Dose at Day 28 and 1 more. Started May 2022; status: completed.
02
Drugs
bavdegalutamide
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT05177042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177042.